Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.

Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...

Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...

Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...